1. Bộ môn Dược Lực, Trường đại học Dược Hà Nội (2007), Sinh lý giải
phẫu, Nhà xuất bản Y học.
2. Bộ môn Dược lý, Trường đại học Dược Hà Nội (2007), Dược lý học tập 1,
Nhà xuất bản Y học, Tr 42-44.
3. Bộ môn Dược lý, Trường đại học Dược Hà Nội (2007), Dược lý học tập 2,
Nhà xuất bản Y học.
4. Bộ môn Hóa sinh, Trường đại học Dược Hà Nội (2005), Hóa sinh học,
Nhà xuất bản Y học, Tr 192-206;
5. Bộ Y tế (2002), Dược thư Quốc gia Việt Nam.
II/ Tiếng Anh
6. Barrera G. et. Al. (2008), “The role of PPAR ligands in controlling growth- related gene expression and their interaction with lipoperoxidation products”, PPAR research 2008: 524671.
7. Barter P.J., Rye K.A. (2008), “is there a role for fibrates in the
management of dyslipidemia in the metabolic syndrome?”,
Arteriosclerosis, thrombosis and vascular biology 28,39.
8. Bourguet w., Germain p., Gronemeyer H. (2000), “Nuclear receptor ligand- binding domains; three- dimensional structures, molecular
interactions and pharmacological implications”, Trends in
9. Burdick A.D., Billity M.T., Giroir E.E., Billin A.N., Willson T.M., Gonzalez F.J., Peter J.M. (2007), “Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delat) inhibits cell growth of human N/TERTlkerotinocytes”, Cell signal 19(6), 1163-1171. 10. Chandra V., Huang P., Hamuro Y., Raghuram S., Wang Y., Burris T.P.,
Rastinejad F. (2008), “ Structure of the intact PPAR-y-RXR-a nuclear receptor compex on DNA”, Nature 456(7220), 35-356.
11.Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. (2001), “Nuclear receptors and lipid physiology: opening the X- files”. Science 294, 1866-
1870.
12. Chen K., Li D., Zhang X., Hermonat P.L., Mehta J.L. (2004), “anoxia- reoxygenation stimulates collagen type-I and MMP-1 expression in
cardiac fibroblasts: modulation by the PPAR-gamma ligand pioglitazone”.
Journal o f cardiovascular pharmacology 44(6), 682-687.
13. Cuzzocrea S. (2004), “Peroxisome proliferator-activated receptor gamma ligands and ischemia and reperfusion injury”. Vascular pharmacology 41, 187-195.
14.Dormandy J.A., Charbonnel B., Eckland D.J.A. et. Al. (2005), “Secondary prevention of macrovascular events in patients with type 2 diabetes in the
PROactive Study (PROspective pioglitazone clinical trial in
macrovascular events): a randomised controlled trial”. The lancet
366(9493), 1279-1289.
15. Eto K., Yamashita T., Matsui J., Terauchi Y., Noda M., Kadowaki T. (2002), “Genetic manipulations of fatty acid metabolism in beta-cells are
16. Food and Drug Administration Advisory Committees Meeting (2010), “Cardiovascular information on Rosiglitazone and Pioglitazone Presented at the July 13 and 14”
17.Gani O. (2008), “ Are fish oil omega-3 long- chain fatty acids and their derivatives peroxisome proliferator- activated receptor agonists?”, Cardio
vascular diabetology 7:6.
18. Germain P., Staels B., Dacquet C., Spedding M., Laudet V. (2006), “Overview of Nomenclature of nuclear receptors”. Pharmacological
reviews 58(4), 685-704.
19.Glass C.K., Rosenfeld M.G. (2000), “ The coregulation exchange in transcriptional functions of nuclear receptors”. Genes & development
14(2), 121-141.
20. Goetze S. et. al. (2002), “Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR gamma ligands”. Hypertension
40(5), 748-754.
21. Goldenberg L, Benderly M., Goldbourt U. (2008), “Update on the use of flbrates: focus on benzafibrate”, Vascular health and risk management
4(1), 131-141.
22.Goodman & Gilman’s (1996), The Pharmacological Basic o f
Therapeutics, 9'*’ Edition, Division of the Me Graw companies. Inc...
23.Hall M.G., Quignodon L., Desvergne B. (2008), “Peroxisome proliferator- activated receptor beta/delta in the brain: facts and hypothesis”, PPAR
research 2008:780452.
24. Hannele Y.J. (2004), “Thiazolidinediones”, The new england journal o f
25. Home P.D. et. al., RECORD study group (2009), “Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial”. The lancet 373(9681), 2125-2135.
26. Home P.D., Pocock S.J., Beck- Nielsen H., Gomis R., Hanefeld M., Jones N.P., Komajda M., McMurray J.J., RECORD study group (2007), “Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis”. The new england journal o f medicine 357(1), 28-38.
27. Jiang C., Ting A.T., Seed B. (1998), “PPAR- gamma agonists inhibit production of monocyte inflammatory cytokines”. Nature 391, 82-86. 28.Jump D.B., Botolin D., Wang Y., Xu J., Christian B., Demeure O. (2005),
“Fatty acid regulation of hepatic gene transcription”, American society for
nutrition 135(11), 2503-2506.
29. Kadowaki T., Hara K., Yamauchi T., Terauchi Y., Tobe K., Nagai R. (2003), “obesity and diabetes: pathophysiological mechanisms and therapeutic approaches molecular mechanism of insulin resistance and obesity”. Experimental biology and medicine 228, 1111-1117.
30. Kapadia R., Yi J.H., Vemuganti R. (2008), “Mechanisms of anti inflammatory and neuroprotective actions of PPAR-gamma agonists”,
Frontiers in Bioscience 13, 1813-1826.
31. Kaul S., Bolger A.F., Herrington D., Giugliano R.P., Eckel R.H. (2010), “Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation”, Circulation 121(16), 1868-1877.
32.Kersten S. (2001), “Mechanisms of nutritional and hormonal regulation of lipogenesis”, EMBO reports 2(4), 282-286.
33. Kintscher U. (2008), “Pharmacological differences of glitazones: does peroxisome proliferator- activated receptor alpha activation make the
difference?” , Journal o f the American College o f Cardiology 52(10), 882- 884.
34.Kintscher U., Law R.E. (2005), “PPAR gamma-mediated insulin sensitization: the importance of fat versus muscle”, American journal o f
physiology endocrinology and metabolism 288(2), 287-291.
35.Klinge C.M. (2000), “ Estrogen receptor interaction with co-activators and co-repressors”. Steroids 65(5), 227-251.
36.Kumar R., Gururai A.E., Vadlamudi R.K., Rayala S.K. (2005), “ The clinical relevance of steroid hormone receptor corepressors”. Clinical
cancer research 11(8), 2822-2831.
37. Kunar R., Thompson E.B. (1999), “The structure of the nuclear hormone receptors”. Steroids 64(5), 1637-1647.
38. Lalloyer F., Staels B. (2010), “Fibrate, Glitazones, and Peroxisome Proliferator-activated receptors”, Arterosclerosis, Thrombosis, and
Vascular Biology 30:894.
39. Lee C.H., Olson P., Evans R.M. (2003), “Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors”,
Endorinology 144(6), 2201-2207.
40.Li Y., Zhang J. et. al .(2008), “Molecular recognition of nitrated fatty acids by PPAR gamma”, Nature structure & molecular biology 15(8), 865-867.
41.Lonard D.M., Kumar R., O’ Malley B.W. (2010), “The SRC Family of coactivators: an entrée to understanding a subset of polygenic diseases?”.
Molecular endocrinology 24(2), 279-285.
42.Mangelsdorf D.J. et. al. (1995), “ The nuclear receptor superfamily: the second decade”. Cell 83(6), 835-839.
43. Marx N. et. al. (2003), “Antidiabetic PPAR gamma-activator
rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease”. Arteriosclerosis, thrombosis and vascular
biology 283-288.
44.Marx N., Duez H., Fruchart J.C., Staels B. (2004), “Peroxisome proliferator- activated receptors and atherogenesis regulators of gene expression in vascular cells”. Circulation research 94:1168.
45.Mazzone T., Meyer P.M., Feinsein S.B. et. al. (2006), “Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 deabetes: a randomized trial”, JAMA 296(21), 2572-2581.
46. Mehta J.L., Hu B., Chen J., Li D. (2003), “Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing
intracellular superoxide radical generation”. Arteriosclerosis, thrombosis
and vascular biology 23(12), 2203-2208.
47. Micalik L., Auwerx J. et. al. (2006), “International Union of Pharmacology. LXI. Peroxisome proliferator- activated receptors”,
Pharmacological reviews 58(4), 726-741.
48. Nathan D.M., Buse J.B., Davidson M.B., Ferranini E., Holman R.R., Sherwin R., Zinman B., American Diabetes Association; European Association for Study of Diabetes (2009), “Medical management of
hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes”, Diabetes Care 32(1), 193-203.
49.NICE clinical guideline 87 .Type 2 diabetes (2009), “ The management of type 2 diabetes”
50.Nolte R.T., Wisely G.B. et. al. (1998), “Ligand binding and co- activator assembly of the peroxisome proliferator- activated receptor- gamma”.
Nature 395, 137-143.
51.Novae N., Heinzel T. (2004), “Nuclear receptors: overview and classification”. Current drug targets- inflammation & allergy 3(4), 335- 346.
52.Nuclear Receptors Nomenclature Committee (1999), “A unified nomenclature system for the nuclear receptor superfamily”. Cell 97,161-
163.
53.Peter J.M., Hollingshead H.E., Gonzalez F.J. (2008), “Role of peroxisome
proliferator-activated receptor beta/delta (PPARbeta/delta) in
gastrointestinal tract function and disease”. Clinical science 115(4), 107- 127.
54.Peters J.M., Gonzalez F.J. (2009), “Sorting out the functional roles of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/deha) in cell proliferation and cancer”, Biochimica et biophysica acta 1796(2), 230-241.
55. Pfitzner A., Marx N., Lubben G. (2005), “Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results
from the pioneer study”, Journal o f the american college o f cardiology
45(12), 1925-1931.
56.Pyper S.R., Viswakama N., Yu S., Reddy J.K. (2010), “ PPAR alpha: energy combusion, hypolipidemia, infammation and cancer”. Nuclear
receptor signaling 8:e002.
57. Reddy J.K. (2001), “Nonalcoholic steatosis and steatohepatitis III. Peroxisomal b-oxidation, PPARa, and steatohepatitis”, American journal
o f physiology gastrointestinal and liver physiology 281(6), 333-339.
58.Reddy J.K., Rao M.S. (2006), “Lipid metabolism and liver
inflammation.il. Fatty liver disease and fatty acid oxidation”, American
journal o f physiology gastrointestinal and liver physiology 290(5), 852-
858.
59.Ricote M., Glass C.K. (2007), “PPARs and molecular mechanisms of transrepression”, Biochimica et Biophysica Acta 2007, 1771(8), 926-935.
60. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. (1998), “The peroxisome proliferator-activated receptor gamma is a negative regulator of macrophage activation”. Nature 391. 9-82.
61.Rodbard H.W. et. al. (2009), “ Statement by an American Association of clinical endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control”.
Endocrine practice 15(6), 540-559.
62. Rosen E.D., Spiegelman B.M. (2001), “ PPAR gamma: a nuclear
regulator of metabolism, differentiation, and cell growth”. The journal o f
63. Schwartz A.V. (2008), “TZDs and bone: A review of the recent clinical evidence”, PPAR research 2008, 297893.
64.Shmia A.M., Staels B. (2007), “Review: Peroxisome proliferator-activated receptor gamma and adipose tissue- understanding obesity-related changes in regulation of lipid and glucose metabolism”, The Journal clinical
endocrinology & metabolism 92(2), 386-395.
65.Smirnov A.N. (2002), “ Nuclear receptors: nomenclature, ligands, mechanisms of their effects on gene expression”. Biochemistry (Mosc) 67, 957-977.
66.Spiegelman B.M. (1998), “PPAR-gamma: adipogénie regulator and thiazolidinedione receptor”. Diabetes 47(4), 507-514.
67.Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J. (1998), “ Cardiovascular drugs: mechanism of action of fibrate on lipid and lipoprotein metabolism”. Circulation 98, 2088-2093.
68. Stamer C.I., Schafer J.A., Heaton A.H., Gleason P.P. (2008), “Rosigltazone and pioglitazone utilization from January 2007 through may 2008 associated with five risk- warning events”. Journal o f managed care
pharmacy 14(6), 523-531.
69.Tetel M.J., Auger A.P., Charlier T.D. (2009), “who’s in charge? Nuclear receptor coactivator and corepressor function in brain and behavior”,
Frontiers in neuroendocrinology 30(3), 328-342.
70.Wahli W., Martinez E. (1991), “Superfamily of steroid nuclear receptors: positive and negative regulators of gene expression”. The FASEB Journal
71.Wammark A., Treuter E., Wright A.P., Gustafsson J.A. (2002), “Activation functions 1 and 2 of nuclear receptors; molecular strategies for transcriptional activation”. Molecular endocrinology 17(10), 1901-1909. 72.Wilcox R., Bousser M.G., Betteridge D.J., Schemthaner G., Pirags V.,
Kupfer S., Dormandy J.;PROactive Investigators (2007), “Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: result from PROactive (PROspective pioglitazone clinical trial in macrovascular events 04)”, Stroke 38(3), 865-873.
73.Willson T.M., Brown P.J., Stembach D.D., Henke B.R. (2000), “The PPARs: from orphan receptors to drug discovery”. Journal o f medicinal
chemistry 43(4), 527-550.
74. Xu H.E., Lambert M.H. et. al. (2001), “Structural determinants of ligand binding selectivity between the peroxisome proliferator- activated
receptors”. Proceedings o f the national academy o f sciences o f the united
states o f america 98(24), 13919-13924.
75. Yamauchi T. et. al. (2001), “The mechanisms by which both
heterozygous peroxisome proliferator-activated receptor gamma
(PPARgamma) deficiency and PPARgamma agonist improve insulin resistance”. The Journal o f biological chemistry 276(44), 245-254.
76.Yang J., Young M.J. (2009), “The mineralocorticoid receptor and its coregulators”. Journal o f molecular endocrinology 43, 53-64.
77.Yang W., Rachez C., Freedman L.P. (2000), “ Discrete roles for peroxisome proliferator- activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators”. Molecular and cellular
78. Zoete V., Grosdidier A., Michielin O. (2007), “Peroxisome proliferator- activated receptor structures: ligand specificity, molecular switch and interactions with regulators”, Biochimica et Biophysica Acta(BBA)-